Guidelines
 /  Guidelines

CURRENT GUIDELINES

Please note that Guidelines marked with an asterisk (*) have been included in the Canadian Medical Association’s Infobase: Clinical Practice Guidelines Database (CPGs)

  • Guideline on the Collection and Testing of Stool Specimens for Bacterial Culture and Antimicrobial Susceptibility Testing*

    (September, 2015)

  • Guideline for the Collection and Testing of Stool Specimens for Ova and Parasites in Symptomatic Patients

    (Revised May, 2015)

  • Guideline on the Investigation of Genital Tract Infections*

    (November, 2015)

  • Guideline on Antibiotic Susceptibilities - Lower respiratory Tract Isolates*

    (June, 2015)

  • Guideline for the Transition from the MDRD to the CKD-EPI Equation for the Calculation of an Estimated Glomerular Filtration Rate (eGFR), and its Interpretation in Concert with the Urine Albumin/Creatinine Ratio (ACR)*

    (April, 2015)

  • eGFR FAQ's

    (April, 2015)

  • Guideline for Adult Lipid Testing (Non-Fasting Option, Reporting of Non-HDL Cholesterol)*
    - CardioRisk Calculator and Framingham Worksheet can be found to the right of these guidelines -

    (Revised November 2013)

  • Guidelines for Ordering Urine Testing for Drugs of Abuse: Targeted and Screening Tests

    (Revised March, 2013)

  • Guidelines for the Use of Laboratory Tests for Assessment of Iron Overload*

    (Revised November, 2012)

  • Guideline for the Ordering of Microscopic Urinalysis

    (Revised June, 2012)

  • Guidelines for the Use of Serum Tests for Iron Deficiency*

    (Revised February, 2012)

  • Guidelines for Testing for Viral Hepatitis*

    (Revised September, 2010)

  • Interpretation of Viral Hepatitis Laboratory Test Results*

  • Guideline for the Appropriate Ordering of Serum Tests for 25-hydroxy Vitamin D and 1,25 dihydroxy Vitamin D*

    (June, 2010)

  • Guidelines for Reporting Laboratory Test Results*

    (Revised September, 2009)

  • Guidelines for Folate Testing*

    (September, 2009)

  • Guideline for the Laboratory Monitoring of Oral Anticoagulation (Warfarin)

    (Revised September, 2008)

  • A Patient's Guide to Anticoagulant Therapy

    (August, 2008)

  • Guidelines for Ordering Serum Levels of Gonadotropins (FSH, LH) and Prolactin CLP–021

    (Revised June, 2008)

  • Guideline for the Use of Laboratory Tests to Detect Thyroid Dysfunction

    (Revised July, 2007)

  • Guidelines for the Rejection of Specimens

    (Revised March, 2007)

  • Pre-Analytical Laboratory Procedures for Medical Office Staff

    (Revised March, 2007)

  • Guidelines for the Retention of Laboratory Records & Materials

    (June, 2006)

  • Guideline for the Collection and Storage of Bacteriology Specimens for Testing

    (April, 2004)

  • Indications for Urine Culture

    (Revised May, 2001)

  • Guideline for the Ordering of Erythrocyte Sedimentation Rate (ESR)

    (Revised March, 2001)

  • Guidelines for the Use of Serum Tests to Detect Renal Dysfunction

    (1996)

COMMUNIQUES

Info

What are Guidelines?

The OAML’s Guidelines for Clinical Laboratory Practice are intended to support improved patient outcomes by encouraging better-informed, clinically relevant decisions about laboratory test ordering and more effective use of health care resources. The OAML strives to improve the quality of patient care by providing community health care practitioners with information about laboratory tests to help ensure that the right test is ordered on the right person at the right time.  The Guidelines provide community health care practitioners with recommendations regarding which clinical situations warrant requesting a test, which test to order, limitations of the test, how to order the test, collect the specimen, and interpret the results.

How are Guidelines Developed?

The OAML, through its Quality Assurance of Clinical Laboratory Practice Committee, co-ordinates the development and dissemination, implementation and evaluation of Guidelines for Clinical Laboratory Practice. A proposed guideline is developed by a working group of the Committee with input from outside experts. The proposed guideline is then submitted to the Committee as a whole and comments are incorporated into a revision of the document. This draft may also be submitted to laboratory Medical Directors, professional associations and other representatives of end users for additional comment. The guideline may be revised in light of these comments and submitted to the OAML Board of Directors for approval. Guidelines are reviewed every 5 years, or as the literature warrants.

Approved Guidelines are distributed to Community Laboratories and by them to their client physicians and other practitioners ordering laboratory tests. There may be additional educational materials produced, if it is thought they might be useful, and these are distributed with the guideline. The guidelines are also available on the OAML’ website.

CardioRisk Calculator

The CardioRisk Calculator is available at http://www.circl.ubc.ca/cardiorisk-calculator.html 
This calculator allows for rapid assessment of Framingham Risk, Cardiovascular Age, Metabolic Syndrome and other factors supporting treatment and management of adults with dyslipidemia and risk of cardiovascular disease.

Framingham Risk Worksheet

A printable version of the Framingham Risk Score worksheet included in the Canadian Cardiovascular Society’s (CCS), 2012 Dyslipidemia Guidelines supplemental material is available under the “Additional Resources” tab at http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_Col_EN.pdf

5000 Yonge St. Suite 1802
Toronto, ON M2N 7E9

P 416-250-8555
F 416-250-8464
E oaml@oaml.com